BioTuesdays
Profound Medical Logo

GMP starts Profound Medical at speculative buy

GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing...

oramed

USPTO extends Oramed patent term

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral...

Senseonics

BTIG starts Senseonics Holdings at buy

BTIG Research has launched coverage of Senseonics Holdings (NYSE MKT:SENS) with a “buy” rating and 12-month price target of $4.50. The stock closed at $2.97 on Monday. “This may be a better way to monitor glucose if...

Tobira Therapeutics

HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday. Tobira is focused on the development of a sole drug candidate...

BioPharmX

HCW starts BioPharmX at buy

H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday. BioPharmX’s lead product is Violet for the treatment of fibrocystic...

AngioDynamics

Canaccord downgrades AngioDynamics to hold

Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten...

oramed

Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed. The double-blind, randomized Phase 2b study of 180 patients with...

Exelixis

Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday. Exelixis is developing small molecule therapies for the treatment of cancer and is focusing...

OraSure Technologies

BTIG starts OraSure Technologies at buy

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.